Reports 2023 revenue EUR 63,809 vs. EUR 0 last year. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx has recently made tremendous progress in its pipeline, with vilobelimab now in Phase III for PG and INF904 emerging as a potentially best-in-class oral C5aR inhibitor with broad commercial potential. It’s with great excitement that we unveil our new pipeline focus directed at sizable markets and unmet needs in immuno-dermatology where our unique approach to C5a and C5aR inhibition may provide significant benefits. We believe that InflaRx can drive incremental pipeline value in this field given our expertise and network. Furthermore, with the potential of INF904 to be a ‘pipeline-in-a-product’, we are considering partnering options to unlock additional value in other areas of interest.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IFRX:
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
- IFRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- InflaRx appoints Medina as Head of Investor Relations
- InflaRx price target lowered to $8 from $9 at H.C. Wainwright
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients